Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

James C. Yao, Jennifer A. Chan, Alain C. Mita, Madan G. Kundu, Karina Hermosillo Reséndiz, Ke Hu, Shoba Ravichandran, Jonathan R. Strosberg, Edward M. Wolin

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

This phase I study aimed at determining the maximum tolerated dose (MTD) and characterizing the safety, tolerability, pharmacokinetics (PKs), and efficacy of pasireotide in patients with advanced neuroendocrine tumors (NETs). Patients were enrolled in two phases: dose-escalation phase (to determine the MTD) at a starting dose of 80 mg pasireotide long-acting release (LAR) i.m. followed by a dose-expansion phase (to evaluate safety and preliminary efficacy). Associations between PK/pharmacodynamic parameters and clinical outcomes were evaluated using linear regression analysis. A total of 29 patients were treated with 80 mg (n=13) and 120 mg (n=16) doses. Most common primary tumor sites included small intestine (44.8%), pancreas (24.1%), and lung (17.2%). No protocol-defined dose-limiting toxicities were observed in the study; however, in post hoc analysis, a higher incidence of bradycardia (heart rate [HR] <40 beats per minute [bpm]) was observed with 120 mg (31.3%) vs 80 mg (0%). Two partial responses (PRs) were observed, both in the 120 mg dose cohort. Pasireotide concentrations correlated with tumor shrinkage, although the association was not statistically significant (P=0.08). Among the biomarkers analyzed, insulin-like growth factor 1 (IGF-1) showed a decreasing trend with increasing pasireotide concentration, while chromogranin A (CgA) and neuron-specific enolase (NSE) levels did not show any dose–response relationship. The most common adverse events in any dose group were hyperglycemia, fatigue, and nausea. MTD was defined at 120 mg for pasireotide LAR in patients with advanced NETs. Although objective radiographic responses were rarely observed with somatostatin analogs, two PRs were observed among 16 patients in the 120 mg cohort. Bradycardia (HR <40 bpm) appears to be a dose-limiting effect; however, the mechanism and clinical significance are uncertain. This study was registered with clinicaltrials.gov (NCT01364415).

Original languageEnglish (US)
Pages (from-to)3177-3186
Number of pages10
JournalOncoTargets and Therapy
Volume10
DOIs
StatePublished - Jun 27 2017

    Fingerprint

Keywords

  • Bayesian logistic regression model
  • Dose escalation with overdose control
  • MTD
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Yao, J. C., Chan, J. A., Mita, A. C., Kundu, M. G., Hermosillo Reséndiz, K., Hu, K., Ravichandran, S., Strosberg, J. R., & Wolin, E. M. (2017). Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors. OncoTargets and Therapy, 10, 3177-3186. https://doi.org/10.2147/OTT.S128547